Visceral obesity and HFpEF: targets and therapeutic opportunities
Language English Country Great Britain, England Media print-electronic
Document type Journal Article, Review, Research Support, Non-U.S. Gov't
PubMed
40113531
DOI
10.1016/j.tips.2025.02.005
PII: S0165-6147(25)00025-2
Knihovny.cz E-resources
- Keywords
- drugs, endocrine, heart failure with preserved ejection fraction, mechanisms, therapies, weight loss,
- MeSH
- Obesity, Abdominal * drug therapy complications physiopathology metabolism MeSH
- Humans MeSH
- Intra-Abdominal Fat metabolism MeSH
- Heart Failure * drug therapy physiopathology MeSH
- Stroke Volume MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
The effectiveness of weight-loss drugs in heart failure (HF) with preserved ejection fraction (HFpEF) highlights the link between obesity (adipose tissue) and HF (the heart). Recent guidelines incorporating the waist:height ratio for diagnosing and treating obesity reflect the growing recognition of the significance of visceral adiposity. However, its unique impact on HFpEF and their complex relationship remain underexplored. With limited treatment options for obesity-related HFpEF, novel disease-modifying treatments are urgently needed. Here, we clarify the relationship between visceral obesity and HFpEF, introducing the concept of the visceral adipose tissue-heart axis to explore its mechanisms and therapeutic potential. We also discuss promising strategies targeting visceral obesity in HFpEF and propose directions for future research.
References provided by Crossref.org
